Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Puma Biotechnology's share price for the quarter that ended in Dec. 2023 was $4.33. Puma Biotechnology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 47.6 Mil. Therefore, Puma Biotechnology's market cap for the quarter that ended in Dec. 2023 was $206.3 Mil.
Puma Biotechnology's quarterly market cap
declined
from Jun. 2023 ($165.7 Mil) to Sep. 2023 ($125.0 Mil) but then
increased
from Sep. 2023 ($125.0 Mil) to Dec. 2023 ($206.3 Mil).
Puma Biotechnology's annual market cap
increased
from Dec. 2021 ($125.2 Mil) to Dec. 2022 ($196.0 Mil) and
increased
from Dec. 2022 ($196.0 Mil) to Dec. 2023 ($206.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Puma Biotechnology's Enterprise Value for Today is $257.6 Mil.
Puma Biotechnology Market Cap Historical Data
The historical data trend for Puma Biotechnology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Puma Biotechnology's Market Cap
For the Biotechnology subindustry, Puma Biotechnology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Market Cap distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Market Cap falls into.
Puma Biotechnology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Puma Biotechnology's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (NAS:PBYI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Puma Biotechnology Market Cap Related Terms
Thank you for viewing the detailed overview of Puma Biotechnology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Puma Biotechnology (Puma Biotechnology) Business Description
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PBYI has been successfully added to your 